Weekly Digest – July 2026 Weekly Digest – July 2026 17 July 2026: NMPA accepts New Drug Application for Trastuzumab Envedotin injection CSPC Pharmaceutical Group announced that China’s NMPA has accepted the new drug application for Trastuzumab envedotin injection, a […]
Weekly Digest – July 2026 Weekly Digest – July 2026 18 July 2026: Medilink announces NMPA acceptance of marketing application for Tam-Peli in 3L+ NPC MediLink Therapeutics announced that China’s NMPA has accepted the new drug application for Tam-Peli, its […]
Weekly Digest – July 2026 Weekly Digest – July 2026 26 June 2026: Datroway recommended for approval in the EU as 1st-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy AstraZeneca and Daiichi Sankyo’s Datroway has […]
Weekly Digest – July 2026 Weekly Digest – July 2026 02 July 2026: FDA alignment to advance ProstACT Global phase 3 trial Telix Pharmaceuticals has reached alignment with the U.S. FDA to advance the ProstACT Global phase 3 trial of […]
Weekly Digest – May 2026 Weekly Digest – May 2026 06 May 2026: HLX43 received PMDA acknowledgment to initiate a global Phase 2/3 trial in squamous Non-Small Cell Lung Cancer Henlius has achieved a key milestone for its anti-PD-L1 ADC […]
Weekly Digest – April 2026 Weekly Digest – April 2026 30 March 2026: Zymeworks receives U.S. FDA Fast Track Designation for ZW191, an FRα-targeting ADC Zymeworks’ FRα-targeting ADC, ZW191, has received FDA Fast Track designation for patients with advanced or […]
Weekly Digest – April 2026 Weekly Digest – April 2026 01 April 2026: RemeGen’s dual-antibody ADC RC288 for the treatment of advanced malignant solid tumors has been officially approved for clinical trials RemeGen’s dual-target ADC, RC288, has received clinical trial […]
Weekly Digest – August 2024 Weekly Digest – August 2024 05 Aug 2024: Salubris Biotherapeutics Announces European Medicines Agency Approval to Initiate a Phase 1 Clinical Trial of JK06, a 5T4-Targeted ADC, in Solid Tumors Salubris Biotherapeutics has received EMA […]
